Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
14,422 results
  • The impact of COVID-19 on ischemic stroke. [Journal Article]
    Diagn Pathol. 2020 Jun 29; 15(1):78.Zhai P, Ding Y, Li Y
  • CONCLUSIONS: We report an even more unusual case, a patient who was hospitalized for right limb weakness and was later diagnosed with COVID-19. Here, SARS-CoV-2 infection caused hypoxemia and excessive secretion of inflammatory cytokines, which contribute to the occurrence and development of ischemic stroke. Once COVID-19 patients show acute ischemic stroke, neurologists should cooperate with infectious disease doctors to help patients.
  • Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy. [Journal Article]
    Thorac Cardiovasc Surg. 2020 Jun 27 [Online ahead of print]Schlachtenberger G, Deppe AC, … Wahlers TCW
  • CONCLUSIONS:  Dual antiplatelet therapy is associated with higher rates of major bleeding. Further studies should examine the difference in the prevalence of major bleeding complications in the different dual antiplatelet therapy regimes in patients requiring urgent surgery.
  • Natural Products as Modulators of CES1 Activity. [Journal Article]
    Drug Metab Dispos. 2020 Jun 26 [Online ahead of print]Qian Y, Markowitz JS
  • Carboxylesterase 1 (CES1) is the predominant esterase expressed in the human liver and capable of catalyzing the hydrolysis of a wide range of therapeutic agents, toxins, and endogenous compounds. Accumulating studies have demonstrated associations between the expression and activity of CES1 and the pharmacokinetics and/or pharmacodynamics of CES1 substrate medications (e.g. methylphenidate, clop…
  • Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. [Review]
    J Clin Med. 2020 Jun 23; 9(6)Numasawa Y, Sawano M, … Kohsaka S
  • Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention has become the standard of care, particularly in patients with acute coronary syndrome (ACS). Current clinical guidelines recommend novel P2Y12 inhibitors (e.g., prasugrel or ticagrelor) in addition to aspirin based on the results of representative randomized controlled trials conducted predominantly in Western countries. T…
  • Platelet Transfusion in Cardiac Surgery: A Systematic Review and Meta-Analysis. [Journal Article]
    Ann Thorac Surg. 2020 Jun 22 [Online ahead of print]Yanagawa B, Ribeiro R, … Canadian Cardiovascular Surgery Meta-Analysis Working Group
  • CONCLUSIONS: After accounting for baseline differences, platelet transfusion was not linked with perioperative complications in cardiac surgery patients. Given the small number of observational studies, these findings should be considered hypothesis generating.
  • Homochiral Covalent Organic Framework for Catalytic Asymmetric Synthesis of Drug Intermediate. [Journal Article]
    J Am Chem Soc. 2020 Jun 23 [Online ahead of print]Ma HC, Chen GJ, … Dong YB
  • (S)-2-(2-Chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetonitrile ((S)-CIK) is a key intermediate to (S)-clopidogrel which is one of the most salable worldwide antiplatelet and antithrombotic drugs. We show herein a facile meth-od for direct synthesis of (S)-CIK via one-pot in situ Strecker reaction using homochiral covalent framework catalyst in a het-erogeneous way. The asymmetric…
  • Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. [Journal Article]
    Stroke. 2020 Jul; 51(7):2058-2065.Meschia JF, Walton RL, … Johnston SC
  • CONCLUSIONS: This substudy of POINT found no significant interaction with CYP2C19 loss-of-function carrier status and outcome by treatment group. Failure to confirm the findings from the CHANCE trial may be because the loss-of-function alleles tested are not clinically important in this context or because the 2 trials had differences in racial/ethnic composition. Additionally, differences between the 2 trials might be due to chance as our statistical power was limited to 50%. Registration: URL: Unique identifier: NCT00991029.
  • How do type of preoperative P2Y12 receptor inhibitor and withdrawal time affect bleeding. [Journal Article]
    Ann Thorac Surg. 2020 Jun 18 [Online ahead of print]Voetsch A, Pregartner G, … Mahla E
  • CONCLUSIONS: Exposure to prasugrel and ticagrelor within 24 hours before CABG increases both calculated blood loss and BARC-4 bleeding as compared to clopidogrel. Although a >48 hours discontinuation substantially reduced calculated blood loss and BARC-4 bleeding across all P2Y12 receptor inhibitors, our single center data further support strict adherence to the 2017 guidelines whenever justified by stable hemodynamics and non-jeopardized myocardium.
New Search Next